Promoted Content
Promoted Content

Find Neurology Drugs in Phase I Clinical Development

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Country filter
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): PF-05251749

            Therapeutic Area: Neurology Product Name: Undisclosed

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Biogen

            Deal Size: $710.0 million Upfront Cash: $75.0 million

            Deal Type: Acquisition January 13, 2020

            Details:

            With this purchase, Biogen plans to develop the Phase 1 asset for the treatment of Sundowning in Alzheimer’s disease (AD) and Irregular Sleep Wake Rhythm Disorder in Parkinson’s disease.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): LP352

            Therapeutic Area: Neurology Product Name: LP352

            Highest Development Status: Phase I Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Arena Pharmaceuticals

            Deal Size: $56.0 million Upfront Cash: Undisclosed

            Deal Type: Financing October 28, 2020

            Details:

            Proceeds from the financing will be used to support the development of LP352 for treatment-resistant developmental and epileptic encephalopathies, and preclinical programs relating to LP143 and LP659 for the potential treatment of microglial neuroinflammatory diseases.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Leronlimab

            Therapeutic Area: Neurology Product Name: PRO 140

            Highest Development Status: Phase I Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 26, 2020

            Details:

            Company is accelerating the filing of a Ph2 protocol to evaluate leronlimab’s potential as a therapeutic for stroke recovery. Administration of leronlimab resulted in approx. 70-75% CCR5 receptor occupancy in the Brain.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Diazepam

            Therapeutic Area: Neurology Product Name: XP-0863

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 20, 2020

            Details:

            The FDA provided feedback that Xeris’ drug development program for XP-0863 could advance directly into a Phase 3 registration study in both pediatric and adult patients with epilepsy.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): ACD856

            Therapeutic Area: Neurology Product Name: ACD856

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 13, 2020

            Details:

            The abstract demonstrates that AlzeCure's leading drug candidate in the company's NeuroRestore platform, ACD856, has the potential for wide use in various types of cognitive memory disorders.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): NBI-921352

            Therapeutic Area: Neurology Product Name: XEN901

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Xenon Pharmaceuticals Inc

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 08, 2020

            Details:

            U.S. Food and Drug Administration (FDA) Requests Additional Non-Clinical Data to Support Dose Justification Before Initiation of a Phase II Clinical Trial with NBI-921352 in Pediatric SCN8A-DEE Patients.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): DNL151

            Therapeutic Area: Neurology Product Name: DNL151

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Biogen

            Deal Size: $2,150.0 million Upfront Cash: $560.0 million

            Deal Type: Licensing Agreement October 07, 2020

            Details:

            The companies will co-develop Denali’s small molecule inhibitors of leucine-rich repeat kinase 2 (LRRK2) for Parkinson’s disease, and will co-commercialize Denali’s LRRK2 products in the United States and China, with shared responsibility for worldwide development costs.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): KCP-506

            Therapeutic Area: Neurology Product Name: KCP-506

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Genentech

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration October 07, 2020

            Details:

            With the extension, Kineta will continue development of α9/α10 nicotinic acetylcholine receptor (nAChR) antagonists and will advance KCP506 through Phase 1 clinical trials. Kineta will also receive an undisclosed payment from Genentech to extend the research collaboration.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): XPro1595

            Therapeutic Area: Neurology Product Name: XPro1595

            Highest Development Status: Phase I Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 05, 2020

            Details:

            The preliminary data, albeit in a small number of patients, demonstrate that XPro1595, when given via subcutaneous injection, decreases neuroinflammation in the arcuate fasciculus.

            Lysosomal Therapeutics

            • Deals

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): LTI-291

            Therapeutic Area: Neurology Product Name: BIA 28-6156

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: BIAL

            Deal Size: $130.0 million Upfront Cash: Undisclosed

            Deal Type: Acquisition October 01, 2020

            Details:

            BIAL has established a new affiliate in the U.S BIAL Biotech Investments Inc. Additionally, BIAL has acquired worldwide rights of LTI-291 and all the Parkinson’s disease research programs of Lysosomal Therapeutics and taken on the entire R&D team.

            PharmaCompass